Effective therapeutic strategies for chest-related disease are still lacking, and many patients have poor survival prognoses. The underlying mechanisms of chest-related disease are complex and involve various signalling pathways. Increasing evidence showed that epigenetics was crucial for the development and therapy of chest-related disease. Epigenetics is the study of acquired changes in chromatin structure that arise independently of change in the underlying DNA nucleotide sequence. Epigenetic changes are reversible and include key processes of DNA methylation, chromatin modifications, nucleosome positioning, and alterations in non-coding RNA profiles. Recently reports showed that pharmacologically targeting epigenetic molecular contributes to diagnosing and treating chest-related disease.
Thus, this research topic accepts research articles, reviews and short communication on epigenetics pharmacological research for chest-related disease, focusing on but not limited to the following subtopics:
• Identification of new epigenetics biomarkers for the diagnosis of chest-related disease;
• Identification of new epigenetics molecular target for the therapy of chest-related disease;
• Discovery of new drugs including small molecule compound and nano delivery system targeting chest-related disease;
• Signs, symptoms and prognosis of chest-related diseases;
• Novel therapeutic approaches to treat chest-related diseases.
Effective therapeutic strategies for chest-related disease are still lacking, and many patients have poor survival prognoses. The underlying mechanisms of chest-related disease are complex and involve various signalling pathways. Increasing evidence showed that epigenetics was crucial for the development and therapy of chest-related disease. Epigenetics is the study of acquired changes in chromatin structure that arise independently of change in the underlying DNA nucleotide sequence. Epigenetic changes are reversible and include key processes of DNA methylation, chromatin modifications, nucleosome positioning, and alterations in non-coding RNA profiles. Recently reports showed that pharmacologically targeting epigenetic molecular contributes to diagnosing and treating chest-related disease.
Thus, this research topic accepts research articles, reviews and short communication on epigenetics pharmacological research for chest-related disease, focusing on but not limited to the following subtopics:
• Identification of new epigenetics biomarkers for the diagnosis of chest-related disease;
• Identification of new epigenetics molecular target for the therapy of chest-related disease;
• Discovery of new drugs including small molecule compound and nano delivery system targeting chest-related disease;
• Signs, symptoms and prognosis of chest-related diseases;
• Novel therapeutic approaches to treat chest-related diseases.